Evidence map›Paper›PMID 41497721›Full record

ArticleJournal of ophthalmology2025

Intravitreal Ranibizumab Injections Significantly Influence Retinal Venous Calibre in Patients With Diabetic Macular Oedema.

Luke K Chehade, Noha Ali, Paul G Sanfilippo, Sukhpal S Sandhu, Lyndell L Lim, Sanjeewa S Wickremasinghe

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Special Issue: Molecular Mechanisms and Treatment of Retinal Diseases.International journal of molecular sciences · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Luke K ChehadeOphthalmology Department, University of Adelaide, Adelaide, South Australia, Australia, adelaide.edu.au.ORCID https://orcid.org/0000-0001-7744-6535
Noha AliCentre for Eye Research Australia Medical Retina Department, The Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.
Paul G SanfilippoCentre for Eye Research Australia Medical Retina Department, The Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.
Sukhpal S SandhuCentre for Eye Research Australia Medical Retina Department, The Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.
Lyndell L LimCentre for Eye Research Australia Medical Retina Department, The Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0003-2491-685X
Sanjeewa S WickremasingheCentre for Eye Research Australia Medical Retina Department, The Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-0752-5876

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To assess changes in retinal vascular calibre following intravitreal ranibizumab treatment in patients with diabetic macular oedema (DMO). Methods: A post hoc analysis of data from a prospective clinical study assessing patients treated with ranibizumab for DMO was conducted. 76 eyes of 67 treatment naive patients were recruited. Patients received three, monthly, ranibizumab injections. From months 3 to 12, ranibizumab injections were administered PRN. Retinal vascular calibre was measured from digital fundus photographs with a semiautomated computer programme (SIVA) and summarised as central retinal artery (CRAE) and vein (CRVE) equivalent. Artery to vein ratio (AVR) was derived from CRAE/CRVE. The primary and secondary outcomes were change in CRAE, CRVE, AVR, CMT and BCVA from baseline to month 2 and 12, respectively. Results: BCVA improved significantly from 60.71 ± 8.24 letters by 6.76 ± 6.40 ( Conclusion: Ranibizumab treatment was associated with a significant reduction in CRVE and increase in AVR. It is possible that the positive effect of ranibizumab therapy on improvements in BCVA and CMT may be related to reduction of retinal venous calibre and hydrostatic pressure.

Indexed as

macular oedemaretinal vesselsvascular endothelial growth factor

Identifiers

PMID41497721
PMCPMC12767068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.